The government is now operating in accordance with the Guidance on Caretaker Conventions, pending the outcome of the 2025 federal election.
CRESEMBA Pfizer Australia Pty Ltd
Product name
CRESEMBA
Sponsor
Accepted date
Jul-2024
Active ingredients
isavuconazonium sulfate
Proposed indication
CRESEMBA is indicated in adults and paediatric patients from 1 year of age for the treatment of
• invasive aspergillosis
• mucormycosis in patients for whom amphotericin B is inappropriate.
• invasive aspergillosis
• mucormycosis in patients for whom amphotericin B is inappropriate.
Application type
C (new indication)
Publication date
Jul-2024